Introduction
The beginning of the third millennium falls very close to the centenary of the discovery of the reninangiotensin system. In 1898 Tigerstedt and Bergman 1 reported that they had obtained, in both watery and alcoholic extracts of the renal cortex of rabbits, material which had a pressor effect on intravenous injection. They named this substance 'renin'. A century later, the renin-angiotensin system is revealed as possessing remarkable biochemical and pharmacological complexity, aspects which have profound evolutionary implications, as shall be discussed herein. This system is widely and deeply involved in diverse physiological and pathological processes, such that drugs designed to influence its different aspects have extensive, and still increasing, application. Whilst, just over a century following its discovery, the full physiological and pathological significance of the renin-angiotensin system remains even now in several respects imperfectly comprehended, its importance cannot be in doubt.
Historical review
A historical review 2 of advancing knowledge and understanding of the renin-angiotensin system was proferred in a chapter of the two-volume study of the system that we edited and which was published in 1993; 3 further details on various aspects appear in relevant individual chapters therein. Additional perspectives are given in a celebratory centenary volume. 4 The following abbreviated account is largely derived from those several sources.
The discovery of renin
Tigerstedt and Bergman 1 achieved remarkably detailed characterisation in their initial studies, demonstrating almost certainly, as was later confirmed, that renin is a protein. Their work further suggested that renin was released into renal venous blood so as to cause its pressor effect; it is now known that renin is indeed secreted into both the renal vein and renal lymphatics. 2 
Goldblatt and renovascular hypertension
Little further work was performed on renin in the early years of the 20th century. Then Goldblatt et al, 5 in 1934, showed that it was possible to produce sustained hypertension by applying constricting clamps to the renal arteries. Surprisingly, although Goldblatt speculated that a humoral substance might be involved in the pathogenesis of this form of experimental hypertension, he did not at first consider renin to be a contender. Nevertheless, others did, and once more renin was successfully extracted from kidneys and partially purified. 6 Even so, the role of the renin-angiotensin system in the causation of renovascular hypertension eventuated as being remarkably complex, and more than 60 years of extensive study, and some fierce controversy, were required to clarify the situation, which in certain respects remains still unresolved. These matters will be considered in more detail later.
Renin as an enzyme
The possibility that renin was an enzyme was raised by Kohlstaedt et al 7 and by Munoz et al 8 in the late 1930s. Extensive studies consequently confirmed that renin itself did not have a direct pressor action, but that it acted upon a plasma substrate (now called angiotensinogen) to form ultimately the vasoactive material subsequently identified as the peptide angiotensin II (Figure 1 ). The comparatively slow and prolonged rise in arterial pressure when renin is injected intravenously is because of the requirement for the generation of angiotensin II in vivo; this contrasts with the more rapid and briefer rise in pressure when preformed angiotensin II itself is given.
Figure 1
Outline of the biochemistry of the renin-angiotensin system (equine renin substrate is indicated, with the differences in composition in man immediately below). In man, the enzyme, renin, cleaves its substrate (angiotensinogen) between leucine and valine in positions 10 and 11 to form the decapeptide, Ang I. In several other species, both positions 10 and 11 of angiotensinogen are occupied by leucine. Converting enzyme removes residues 9 and 10 (histidine and leucine) to form the active octapeptide, Ang II. Removal of aspartic acid from position 1 forms the heptapeptide, Ang III. In the rat, the 2-10 nonapeptide is present in blood, and Ang III can be formed directly from this nonapeptide by the action of converting enzyme. (From Robertson 2, 3 with permission.)
The renal juxtaglomerular cells
The Belgian histologist and physiologist Goormaghtigh 9 in 1945 recognised the juxtaglomerular cells on the renal afferent arteriole to be the principal source of renin, as has since been thoroughly confirmed.
Long-term pressor effect of renin
Pickering perceived that renin was well suited to serve as a long-term regulator of the circulation, and he and his colleagues 10 executed experiments of considerable difficulty given the apparatus then available in 1950, demonstrating that intravenous infusion of renin for up to 18 days' duration could initiate and then sustain hypertension throughout that period.
The slow pressor effect of angiotensin II
Thus far, the pressor action had been studied at doses sufficient to raise arterial pressure immediately, presumably via direct vasoconstriction. In 1963 Dickinson and Lawrence 11 observed that the intravenous infusion of angiotensin II at low doses, having no immediate effect on arterial pressure would, over the course of several days, result in a gradual, and eventually very marked, rise in pressure. Angiotensin II could thus be shown to elevate its own acute pressure dose-response curve, such that a direct response could be superimposed on a slow rise that had reached a plateau, the combined effect exceeding that of the maximum simple initial direct response.
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Structure of angiotensin
Skeggs et al 13 found that the essential component of angiotensinogen is a tetradecapeptide from which renin splits off first a decapeptide, the inactive angiotensin I. Angiotensin I is then cleaved by angiotensin-converting enzyme (ACE) to form the main active component of the sytem, the octapeptide angiotensin II (Figure 1 ). The amino acid sequences of bovine and equine angiotensin were elucidated respectively by Elliott and Peart, 14 and by Skeggs et al. 15 Angiotensin was shortly afterwards synthesised by Schwyzer and colleagues.
was then further emphasised by the finding 24, 25 that sodium restriction enhanced the stimulant effect of angiotensin II on aldosterone secretion, while simultaneously depressing the pressor effect, both phenomena obviously helping to promote sodium conservation at a time of its deficiency.
Renin and plasma sodium concentration
An inverse association between plasma sodium concentration within the last week of life and subsequent granularity of the juxtaglomerular cells at post mortem was demonstrated in 24 patients with diverse medical conditions. 26 Subsequent workers showed that plasma levels of renin and sodium were related inversely in patients with hypertension and heart failure. 27 These associations pointed to functional interactions between activity of the reninangiotensin system and water balance in particular, which could be accounted for in part by actions of angiotensin II on thirst, antidiuretic hormone release and water retention by the kidney (Figure 2 ).
Renin assays
The early 1960s saw the introduction of assays sufficiently sensitive to detect renin in peripheral blood. 28 In many early methods, [29] [30] [31] a plasma sample was incubated in vitro, and the angiotensin generated from the interaction of endogenous active renin with angiotensinogen was then measured ('plasma renin activity'; PRA). It will be apparent that PRA depended on the respective concentrations of both active renin and of angiotensinogen in the sample. While such PRA measurements should reflect broadly the capacity of the plasma sample to generate angiotensin II, no distinction between the separate concentrations of angiotensinogen and active renin could be made with this approach. Unfortunately also, because several such PRA assays were (and often remain today) rarely standardised, quantitative comparison of results over time, or between laboratories, was hardly ever possible.
A different problem arose with some early methods for the assay of plasma renin concentration (PRC). 32, 33 During extraction, inactive prorenin could be activated, and such procedures thus gave a measure of total, rather than of active, renin concentration.
While studies employing those early PRA and PRC assays provided much valuable information, their limitations have inevitably become more obtrusive.
Circulating inactive renin (prorenin)
As mentioned in the foregoing paragraphs, it became evident that a substantial proportion of circulating renin was in an inactive form (prorenin). Appropriate assays were hence developed for the separate assessment of prorenin. [34] [35] [36] [37] [38] The relative proportions of active renin and prorenin vary very considerably in different circumstances and diseases ( Figure 3 ).
Angiotensin assays
Practicable and reliably accurate methods for the assay of angiotensin II in the circulation were developed from the early 1970s on. 39 (Assay of circulating angiotensin I, though it was also accomplished, 39 was less often needed.) Initially, and, largely because of the technical demands, particularly during the administration of ACE inhibitors, only a few laboratories undertook these procedures. They provided however, two major investigational advantages. First, results could be more readily quantified and compared than was the case with renin assay. Second, because pure synthetic angiotensin II was available and suitable for administration to man and to laboratory animals, doseresponse curves could be determined, thus permitting quantitative analysis of the renin-angiotensin Figure 3 The relation between the percentage of enzymically active renin and the total renin (prorenin plus active renin) concentration in plasma. (From Skinner 79 with permission.) system in various physiological and pathophysiological circumstances. Such a numerate approach is of course crucial to a proper evaluation of a hormonal system.
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Renin in extrarenal tissues
Bing and his colleagues pioneered the study of renin in extrarenal tissues, early work from their Danish laboratory reporting the presence of renin in uterus and salivary glands. 41, 42 Renin is now recognised as being widely distributed, and is detectable in, for example, also heart, 43 blood vessels, 43 adrenal cortex, 44 ovary, 45 amniotic fluid, 46 testis, 47 epididymis, 47 eye, 48 and brain.
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Antagonists and inhibitors of the reninangiotensin system
The introduction and deployment of drugs acting against the renin-angiotensin system began in the 1970s. From that time the specificity, and hence the relevance, of these agents has progressively been refined. Early studies employed beta-adrenergic blockers. While these drugs do, inter alia, lower plasma renin, their antihypertensive effect, for example, cannot be fully explained by suppression of renin release, 50 and thus evaluation of their influence in terms of the renin-angiotensin system has to be cautious.
Although ACE inhibitors are more specific to the renin-angiotensin system than are beta-blockers, at least part of their overall effect could reflect enhancement of bradykinin. 51 Angiotensin II antagonists 52 were developed initially as variants of the octapeptide angiotensin II molecule capable of blocking angiotensin II receptors. While their experimental application provided a wealth of information concerning the physiology 53 and pathophysiology 54 of the renin-angiotensin system, their need for parenteral administration restricted clinical application. Further, several of such analogues of angiotensin II possessed some agonist activity which could hinder ready interpretation of results. For example, one of the most widely used of these agents, saralasin, was sufficiently agonistic to induce the slow pressor effect when administered over several days to rats. 55 The structurally quite distinct orally-active antagonists of the angiotensin II AT 1 receptor represented a major advance, 52, 56, 57 enabling indefinite clinical inhibition of the renin-angiotensin system more specifically than that achieved by ACE inhibitors, and inter alia avoiding the troublesome cough which can accompany use of the latter.
Numerous effective inhibitors of the enzyme renin itself have also been developed, and their efficacy and biochemical sequelae clearly elucidated. 58 Thus far however, their clinical application has been limited by their modest oral absorption and rather brief duration of action.
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Renin: purification and structural elucidation Progressive biochemical developments from the 1960s on permitted the isolation and characterisation of renin itself in pure and stable form; determination of its three-dimensional structure; and delineation of its active site.
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The renin-angiotensin system: present cognizance
The foregoing historical account is by no means comprehensive, but is intended to provide a brief survey of some of the major progressions in the understanding of the system. Our present knowledge can be summarised here.
The basic biochemistry and principal actions of the renin-angiotensin system are shown in Figure 2 . Angiotensin II can be seen to have a range of physiological and pathophysiological effects. It is vasoconstrictor, raises blood pressure by both an immediate and a slower mechanism, stimulates the secretion of aldosterone and vasopressin, facilitates the sympathetic nervous system at several levels, inhibits vagal tone, promotes thirst and sodium appetite, and produces a range of direct renal responses. Interaction with the atrial natriuretic peptide system is complex. 61 Infusion of atrial natriuretic peptide (ANP) lowers renin and angiotensin II, while there are reports of angiotensin II administration stimulating ANP release. 62 The control of renin secretion has turned out to be more complex than was realised. Whereas it was clear that a renal afferent arteriolar baroreceptor, the macula densa, sympathetic innervation of the kidney and various hormones (angiotensin II, antidiuretic hormone and prostaglandins) provided important input signals to renin release, 63 it is now understood that additional factors such as nitric oxide, 64 the natriuretic peptides, [65] [66] [67] [68] endothelin, 69 and adrenomedulin, 70 for example, modulate renin release.
Two principal angiotensin II receptor subtypes have been identified, AT 1 and AT 2 . 71 The AT 1 receptor mediates those effects enumerated above. Some possible physiological roles of the AT 2 receptor 72 are shown in Table 1 . It also seems likely that the AT 2 receptor is involved in the development of the kidney and urinary tract. [73] [74] [75] The ACE gene is very widely expressed, perhaps ubiquitously, through the body. 76 While the primary sites of production of renin and of angiotensinogen are respectively kidney and liver, renin and angiotensinogen genes are extensively manifested in other tissues, many of which, as was stated in the preceding section, have been shown to contain renin. Thus possible local autocrine and paracrine renin-angiotensin systems assume potential physiological, pathological, and perhaps therapeutic, importance. Thus far however, such local tissue renin-angiotensin systems remain, by comparison with circulatory aspects, but sparsely explored.
Phylogenetic and evolutionary aspects
The foregoing sections have considered exclusively mammals, and especially man. In a detailed review, 77 Henderson and Deacon have described the expression and actions of different components of the renin-angiotensin system also in other vertebrate classes. Despite inevitable gaps in the record, the renin-angiotensin system has been identified, in varying complexity, in Agnatha (Cyclostomata); cartilaginous fishes; bony fishes; amphibians; reptiles; and birds. It was in that review speculated that phylogenetically some of the earliest functions of the renin-angiotensin system involved, broadly, the changing requirements to obtain, retain, or excrete water; and to retain or excrete sodium. The regulation of arterial pressure, locally and/or systemically, could thus readily be envisaged as an early necessary acquisition to the range of actions. A major event in vertebrate phylogeny, with obvious and weighty implications for the renin-angiotensin system, was the adoption of a terrestrial habitat.
Henderson and Deacon 77 regard the present conspicuous interplay between the renin-angiotensin system, adrenal cortex, atrial natriuretic peptide, and the kidney as indicating convergent evolution, given that the demands of salt economy amongst contemporary vertebrates are so diverse. As they note, it is remarkable that such relatively uniform statements concerning the physiological spectrum of actions of angiotensin II can be sustained. They further speculate that the renin-angiotensin system may not be unique to vertebrates, but could be more widely represented and influential in the animal kingdom.
Thus, as we ourselves remarked in more detail elsewhere, 78 the renin-angiotensin system appears to have undergone repeated modification and diversification, being adapted time and again through the course of evolution to mediate different physiologi-
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cal and pathophysiological requirements in a wide range of tissues, organs, environments, and syndromes.
These considerations can help to rationalise the present evident complexity of the renin-angiotensin system as observed in man (Figures 1 and 2 ). If we restrict our attention just to the circulation, we observe, in peripheral plasma, the active enzyme renin, the concentration of which is delicately regulated. The concentration of its substrate, angiotensinogen, is controlled largely, but not entirely, by other, independent mechanisms. Concurrently, substantial quantities of inactive prorenin, widely variable in its proportion to active renin in different circumstances, also circulate ( Figure 3) . The possible functions of prorenin remain imperfectly defined, albeit fiercely argued. 79, 80 The principal product of the reaction of renin with angiotensinogen, angiotensin I, is inactive; two amino acid residues require to be removed by the action of ACE before the active octapeptide angiotensin II is formed. Further truncation forms the heptapeptide angiotensin III, [81] [82] [83] with generally more muted, but still discernable, physiological actions. Angiotensin III has been proposed as, inter alia, having a distinct depressor action mediated via AT 1 receptors. 82 Additionally, there is evidence of pathways alternative to those described above for the generation of angiotensin II and angiotensin III. 83 Such elegant biochemical complexity denotes the requirement, adequately fulfilled, to deliver appropriate, but often very different, concentrations of active peptide at several tissues and organs, thus achieving regulated physiological function while minimising (but not always circumventing) the risks of forming or delivering toxic concentrations at any given site. Such biochemical virtuosity can be illustrated by considering in some detail the involvement of the renin-angiotensin system at different stages of the pathogenesis of just two conditions, renovascular hypertension and cardiac failure, as shall be presented shortly. Moreover, such discussion is concerned exclusively with circulatory aspects; to these must be added the presently much less clearly comprehended local paracrine and autocrine functions of the renin-angiotensin system.
Physiological and pathophysiological involvement of the renin-angiotensin system
It will be apparent from the foregoing account that the renin-angiotensin system is intricately involved in a wide diversity of physiological and pathophysiological circumstances. The system is pathogenically responsible wholly or partly for some syndromes, such as renovascular hypertension, and is probably concerned with others. Table 2 provides a list of conditions in which the renin-angiotensin system is variously stimulated or depressed. A detailed appraisal of all of these lies beyond the scope of the present review. Just two syndromes, renovascular hypertension and cardiac failure, will be considered here in some detail so as to indicate the complexity of the participation, and the thera- peutic relevance of drugs antagonistic to, the reninangiotensin system.
Renovascular hypertension
Renovascular hypertension 84, 85 occurs in two pathophysiologically distinct forms. Unilateral renal artery stenosis, the opposite kidney and renal artery remaining intact, corresponds to the Goldblatt twokidney one-clip experimental model. Less often encountered is hypertension due to stenosis of the artery to a sole remaining kidney, corresponding to the Goldblatt one-kidney one-clip model. Bilateral renal artery stenosis with hypertension has as its experimental counterpart Goldblatt two-kidney twoclip hypertension; pathogenesis in this variety is similar to that in the one-clip one-kidney model.
In two-kidney one-clip hypertension, initiation of hypertension is due to increased renin release from the clipped kidney and thus to the immediate direct pressor effect of the elevated peripheral plasma angiotensin II concentration. Concurrently, renin secretion from the contralateral normal kidney is suppressed. Continued exposure to elevated plasma angiotensin II, even if the rise is only modest, results in an upward shift of the angiotensin II/pressor dose-response curve. Thus in the established clinical phase of hypertension, there may be only modest elevation of peripheral levels of renin and angiotensin II. Indeed in some cases values may be in the upper part of the normal range. In this form of hypertension, blood pressure elevation is dependent, in both the phases described, on activation of the renin-angiotensin system. Hypertension can develop in the absence of changes in sodium balance, and is not prevented by sodium restriction. Indeed, with severe unilateral renal artery stenosis or occlusion, frank and progressive sodium depletion can develop, with consequent ever-higher plasma renin and angiotensin II concentrations, and worsening hypertension. This is the hyponatraemic hypertensive syndrome, which can often evolve into frank malignant hypertension. This form of hypertension usually responds to reconstruction of the affected renal artery, to unilateral nephrectomy, or to the administration of antagonists of the renin system, such as ACE inhibitors. However, ACE inhibition will nearly always worsen the already impaired function of the affected kidney.
Hypertension resulting from narrowing of the artery supplying a sole remaining kidney is not usually dependent on an initial rise in renin, even though this can be shown usually to occur transiently. In the established phase there is often modest expansion of body sodium content, accompanying normal or low plasma levels of renin and angiotensin II. There may later, with marked renal artery narrowing, be progression to a terminal phase of severe hypertension and uraemia, with then an increase in plasma renin and angiotensin II. Surgical relief of the renal artery stenosis can be curative. Combined sodium deprivation and pharmacological antagonism of the renin system will lower blood pressure, but at the expense of further impairing renal function. Administration of an antagonist of the reninangiotensin system in the terminal phase of severe hypertension and uraemia will cause profound hypotension, worsening uraemia, and early death.
The usual causes of clinical renovascular hypertension are arterial atheroma (atherosclerosis) and, less often, fibromuscular dysplasia. The latter has a familial predisposition. Several commentators have warned that renovascular lesions often pass unrecognised clinically, with the therapeutic dangers indicated herein if, for example, ACE inhibitors are administered. Even so, it must be emphasised that the coexistence of a renal artery stenosis with hypertension does not establish cause and effect, and is alone insufficient for the diagnosis of true hypertension of renovascular origin.
Cardiac failure
The exigencies of clinical practice have obviously restricted studies of the renin-angiotensin system in untreated heart failure in man, and there is for equally obvious reasons little or no information on changes in renin or angiotensin II as the disease evolves. 86, 87 One early report 88 on 21 patients with untreated heart failure found plasma renin concentration to be subnormal in three, within the normal range in twelve, and high in six subjects. Most importantly, plasma sodium concentration was closely correlated inversely with plasma renin in these untreated patients (r = −0.87; P Ͻ 0.001); with therapy that significant inverse relationship was maintained, while becoming less close (r = −0.55). Later studies from the same department 89 concerning treated heart failure showed a highly significant inverse correlation between plasma active renin concentration and both plasma potassium and total body potassium.
Experimental animal studies have shown that broadly, 86, 87 and with some inconsistencies, there is in cardiac failure an initial rise in circulating renin, often to very high levels, with a parallel increase in plasma aldosterone. This early rise in renin is almost certainly limited, and to a very varied extent, by the inhibitory action of an antecedent or concurrent increase in atrial natriuretic peptide, which restrains renin secretion. With progression of heart failure, and the achievement of a new steady state of sodium and fluid retention, plasma renin values attain a plateau or may even decline.
Activation of the renin-angiotensin system in cardiac failure is thus seen as central to its pathophysiology. Such enhanced renin secretion is crucially concerned with modifications of renal and cardiac function; in central and peripheral haemodynamics; aldosterone secretion; sodium and water balance; total body potassium and plasma potassium; and activation of the sympathetic nervous system. Almost certainly, and via several of these mechanisms, the renin system is a potent arrhythmogenic influence.
It is scarcely surprising therefore that inhibition of the renin-angiotensin system in clinical heart failure, employing ACE inhibitors or orally-active angiotensin II antagonists, almost always on a background therapy comprising digitalis plus diuretics, has shown major benefit, distinct from, and superior to, other forms of vasodilator treatment. [90] [91] [92] Such renin-angiotensin antagonism has consistently been revealed as relieving symptoms and increasing exercise capacity, slowing the progression of left ventricular dysfunction, and extending life expectancy. Similar benefits have been found with ACE inhibition given to patients suffering myocardial infarction and with but modest evidence of cardiac functional impairment. 87, 93 Despite the inevitable lacunae in our knowledge, the involvement of the renin-angiotensin system in cardiac failure provides an elegant example of purposeful physiological evolution. 78 In normal man, the renin-angiotensin system and the atrial natriuretic peptide system subserve opposing functions: the former to protect, inter alia, against sodium and volume depletion, the effects of haemorrhage, and hypotension; the latter to prevent or limit salt and water overload. Thus in normal physiology there is a consistent inverse correlation between circulating atrial natriuretic peptide and both renin and angioJournal of Human Hypertension tensin II. 61 This inverse relation is not merely a result of passive responses to opposing forces; increases in atrial natriuretic peptide within the physiological range reinforce that inverse correlation by inhibiting renin secretion. The supervention of cardiac failure requires however that atrial natriuretic peptide and renin be recruited together; atrial natriuretic peptide to limit the abnormal tendency to salt and water retention, renin to help sustain renal function despite the reduction in renal blood flow. The concomitant increase in both atrial natriuretic peptide and renin is contrived because the normal inhibitory action of the former on renin secretion is lost or markedly diminished when renal perfusion is impaired, 61 as it is from the onset in cardiac failure. Thus in heart failure, atrial natriuretic peptide and renin are both secreted in enhanced amounts, and their respective concentrations in peripheral blood are, quite abnormally, positively correlated. Moreover, in these circumstances their usually conflicting actions are modified so that the two systems become mutually reinforcing. In cardiac failure, atrial natriuretic peptide minimises some of the unwanted peripheral effects of the renin-angiotensin system, such as stimulation of aldosterone secretion, while enhancing its beneficial renal actions.
Currently active topics
The range of actions of the renin-angiotensin system shown in Figure 2 , and the wide variety of physiological and pathophysiological processes enumerated in Table 2 will indicate that because so many and diverse topics are concerned, and under continuous exploration, only a few selected aspects can be mentioned here.
Antihypertensive and cognate therapy
The ACE inhibitors are well-established as a major class of antihypertensive drug. 94 They are as effective as other drug types, with the advantage of a relatively low burden of side effects, of which occasional troublesome cough is the most prominent. 95 There are good reasons to explore possible additional benefits of ACE inhibitor therapy over that employing alternative agents in limiting cardiovascular complications. Administered angiotensin II has been repeatedly shown to cause arterial, cardiac and renal lesions. 96 These aspects are also discussed in more detail later. Angiotensin II has also been implicated as a trophic factor in promoting remodelling of cardiac and resistance arterial musculature, 97 the therapeutic reversal of which should prove especially beneficial. Neither the CAPPP study 98 nor the Swedish STOP-2 trial 99 revealed any unequivocal differential benefit of ACE inhibitor, or ACE inhibitor based therapy versus that with longer-established drug classes. However, the HOPE study, 100 which recruited subjects at high risk of cardiovascular complications, of whom 47% were regarded as 'hypertensive', did clearly indicate that ACE inhibitor treatment was especially protective against cardiovascular complications. All the fore-going trials [98] [99] [100] were prospective. To complicate matters further, whereas STOP-2 99 showed no differential benefit between ACE inhibitor and calcium antagonist therapy, a retrospective evaluation of hypertensive patients suggested that ACE inhibitors conferred better survival, and calcium antagonists a poorer outcome. 101 Another retrospective survey suggested that ACE inhibitors, used in the treatment of hypertension, could incidentally protect against the development of malignant disease. 102 There are plausible reasons why this might be so, since angiotensin II can promote cellular replication and enhance angiogenesis, both effects being counteracted by ACE inhibitors. In theory, at least, angiotensin II antagonists (which block the AT 1 receptor but stimulate the AT 2 receptor) might prove even more efficient than ACE inhibitors in preventing development of neoplastic disease. 103 A further observation 104 is that ACE inhibitors can reduce the risk of pneumonia in elderly patients.
All of these aspects require clarification or substantiation, and are indeed under further detailed scrutiny.
As was described earlier, ACE is not specific for the conversion of inactive angiotensin I to active angiotensin II, but is responsible also for the breakdown of bradykinin into inactive fragments. Thus ACE inhibition will potentiate the action of such kinins, and some of its consequences, including possibly the troublesome cough, could have that origin. 95 The more recently introduced orally-active antagonists of angiotensin II which block the AT 1 receptor are more specific to the renin-angiotensin system. 52, 105 Clinically, they appear thus far to possess the therapeutic attributes of ACE inhibitors, while circumventing some disadvantages, most obviously cough.
Another aspect of the use of selective AT 1 blocking drugs is that unopposed angiotensin II actions via AT 2 receptors should be exposed, thereby clarifying the physiological functions of the latter. [106] [107] [108] [109] [110] There is some evidence that such AT 2 stimulation is additionally vasodilator, and, as mentioned above, might inhibit neoplasia. 103 However, at present it remains uncertain whether clinically such AT 2 stimulation would be beneficial, adverse, or neutral.
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ACE inhibition and renal protection
Macroalbuminuria is almost invariably indicative of renal disease. 111 Nevertheless the full pathological and prognostic significance of microalbuminuria remains uncertain. There have been suggestions 111, 112 that it predicts cardiovascular risk and renal deterioration in hypertension although this has not been confirmed by all. 113 While some workers 114 have queried the matter, microalbuminuria may perhaps identify patients with high blood pressure in whom renal function may deteriorate especially rapidly. 112 Irrespective of hypertension, microalbuminuria is a feature of diabetes mellitus. 112, 115 Both in hypertensive and non-hypertensive subjects, with or without diabetes mellitus, [116] [117] [118] [119] [120] [121] [122] [123] ACE inhibitors have been shown to be highly effective, and often superior to earlier approaches, notably beta-blockade and calcium antagonist therapy in limiting micro-and macro-albuminuria, and in slowing a decline in renal function. Captopril was more effective than older drugs in preventing the onset of diabetes mellitus in hypertension. 98 Irrespective of hypertension, ramipril limited cardiovascular and renal morbidity in diabetic patients. 124 More limited data indicate that angiotensin II antagonists possess similar properties. 125 It is stressed that the benefits of ACE inhibitors in diabetes are probably independent of the antihypertensive action. 124 
Genetic aspects
One of the most exciting fields of development linking the renin-angiotensin system with hypertension concerns genetics. 76, [126] [127] [128] [129] [130] [131] [132] The genetics of four principal components of the system, renin, angiotensinogen, ACE, and angiotensin II receptors, as well as of more peripheral, but related aspects, have been studied. Requiring emphasis is that the association of a form of hypertension with a genetic locus does not necessarily imply that there exists in that element a functional alteration which is responsible for the hypertension; the relevant modification might be near, but outside, the particular gene. Not surprisingly, information is less extensive and less consistent concerning hypertension in man than in various animal models.
Many human studies of renin gene polymorphism in relation to hypertension have been negative. 76, 131, 133 However, an association between renin gene restriction fragment length polymorphism, ethnicity, and hypertension has been reported, 134 albeit without accompanying elevation of plasma renin activity. 135 There have been numerous reports of associations, possibly causal, between molecular variants of the gene for angiotensinogen and essential hypertension and its complications in man. [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] Ranged against these is a series of contrary findings. [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] Possible reasons for these major discrepancies have been debated at length. 139, 153, 162, 165, 166 Critics have, with obtrusive disapprobation, considered some of the early positive surveys to have lacked statistical power, to have incurred selection bias and confounding, and even to have been subject to basic laboratory errors in genetic analysis.
Association of polymorphism of the ACE gene 127, [167] [168] [169] [170] [171] [172] with human essential hypertension has been reported by some [173] [174] [175] [176] [177] but by no means all, 159, 164, 171, [178] [179] [180] [181] [182] [183] [184] [185] workers. Irrespective of hypertension, there is extensive, but also controversial, evidence of variations in the ACE genotype being linked to cardiovascular and renal morbidity. 151, 169, 170, [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] Other investigators have failed 152, [196] [197] [198] [199] [200] to confirm the described associations, and several cautionary criticisms 200, 201 have been directed to the positive reports.
Genetic polymorphism of the angiotensin II AT 1 receptor has been recognised, 126 and there have been suggestions of associations of AT 1 receptor variations severally with plasma renin activity, 202 hypertension, 202 and coronary artery disease. 203 Once again, others 163, 204, 205 have failed to confirm the suggestions and have questioned the value of these approaches.
Bianchi and his colleagues have made detailed and extensive studies [206] [207] [208] [209] [210] of adducin, a heterodimeric protein which probably regulates cell-signal transduction via changes in the actin cytoskeleton and hence renal tubular sodium reabsorption. They found evidence that ␣-adducin gene polymorphism is associated with some cases of essential hypertension in man, with plasma renin activity being lower in the predisposed subjects. 209 The findings have been supported by some, 211, 212 but not all, [213] [214] [215] [216] other workers.
The foregoing is necessarily a very abbreviated account of a complex and rapidly expanding field of investigation. This shows promise of becoming one of the most fiercely controversial areas of an already highly fractious topic. One clearly commendable accompaniment is that the interest in individual components of the system, for example renin, angiotensinogen, and angiotensin II AT 1 receptors, has become focused. These entities now require to be addressed by specific assays and/or characterisation.
The future
Speculation on likely impending developments concerning the renin-angiotensin system is certain to involve errors. As the old Irish saying has it, prediction is hazardous, especially in relation to the future. Nevertheless, some topics are proferred here, several, necessarily, deriving from the preceding section.
Human pregnancy
It has been well-established for over 30 years, that plasma renin, angiotensinogen, angiotensin II, and aldosterone are markedly increased, to a very variable degree, from an early stage and throughout human pregnancy. 217 With pregnancy-induced hypertension, the increases are relatively less. 218 Despite extensive investigation, proper comprehension of the physiological implications remains elusive. A steady, but possibly still protracted, advance can be predicted.
Renin and cardiovascular risk
There are sound experimental reasons for supposing that high levels of circulating renin and hence of angiotensin II could predispose to a range of cardiovascular lesions in hypertension. The experimental infusion of angiotensin II can cause necrotizing arterial lesions, multifocal myocardial lesions, and renal tubular necrosis. 96 At the lower rates of administration myocardial necroses have been seen with plasma concentrations of angiotensin II likely to be encountered clinically. However, translating this extensive experimental information into clinical evidence of increased morbidity with elevated
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The findings of Meade et al 219, 220 have tended to refute such an association. They found that low, rather than high, plasma renin activity was likely to be associated with increased organ damage in hypertension; in normotensive men moreover, they saw no relationship between plasma renin activity and either myocardial infarction or sudden death from likely coronary artery disease.
By contrast, a series of epidemiological surveys by Alderman et al [221] [222] [223] [224] [225] [226] [227] indicated that low urinary sodium and either observed or presumed elevated plasma renin activity was associated with a greater risk of myocardial infarction and both cardiovascular and all-cause mortality. These observations led Alderman et al to question the safety of dietary sodium restriction in the treatment of hypertension. The aforementioned HOPE trial, 100 and the retrospective studies from the Glasgow Blood Pressure Clinic, 101, 228 in which ACE inhibitors limited cardiovascular morbidity, accord with the speculations of Alderman et al. Nevertheless, the various papers by Alderman et al were, not surprisingly, subjected to vigorous attack, [229] [230] [231] [232] [233] [234] [235] [236] not least from advocates of dietary salt restriction. Even were dietary sodium restriction confirmed as predisposing to myocardial infarction, elevation of plasma renin and hence of angiotensin II would not necessarily be the sole, or even principal cause of the problem. The highly significant increases in plasma total and low density lipoprotein (LDL) cholesterol which are also induced by salt restriction 237 would require to be taken into account. This is an area of controversy which will surely receive much investigational attention in the immediate future.
Endothelium
Burgeoning interest especially over the final years of the 1990s in endothelium-derived vasodilators such as nitric oxide and vasoconstrictors such as endothelin has generated a wealth of data concerning the endothelium in relation to hypertension and arterial disease. Interactions with the renin-angiotensin system are prominent herein. The endothelium synthesizes renin locally, while ACE, which both generates angiotensin II and inactivates bradykinin, is abundantly expressed at the surface of endothelial cells. [238] [239] [240] Endothelin-1 has been shown to augment the pressor action of angiotensin II, 241 whereas blockade of endothelin receptors reportedly prevents the pressor and renal (but not dipsogenic) actions of angiotensin II. 242 Inhibition of nitric oxide synthesis with L-NAME activates vascular ACE and causes oxidative stress. 243 Angiotensin II can stimulate nitric oxide and oxygen radical release simultaneously. 244 An ACE inhibitor, captopril, in contrast to the calcium antagonist nifedipine, has been shown to improve endothelium-dependent vasodilation in hypertensive patients. 245 The administration of ACE inhibitors has been demonstrated to protect endothelial vasomotor function by inducing the local accumulation of bradykinin, stimulating
Journal of Human Hypertension autacoid formation, and to inhibit secretion of endothelin-1, 246, 247 although not all reports have been positive. 248 Local generation of angiotensin II probaby facilitates potentially harmful neointimal proliferation after injury, thus offering another therapeutic target for ACE inhibition. 249 Such notions are not exclusive to the peripheral arteries; coronary kinin generation has been reported as mediating nitric oxide release. 250 Somewhat inconsistent findings have emerged concerning the interrelation of angiotensin II with nitric oxide release. Hennington et al 251 reported that angiotensin II stimulated nitric oxide synthase. However, long-term ACE inhibition evidently enhanced the availability of nitric oxide; 246 bradykinin accumulation might of course have contributed to this latter observation.
A somewhat separate, but very pertinent report, especially in relation to the aforementioned effect of angiotensin II in facilitating cardiac remodelling and causing myocardial lesions, was published by Takizawa et al. 252 These workers found that nitric oxide modulated the proliferation of fibroblasts with angiotensin II-induced cardiac fibrosis.
Although data are short of definitive, there is suspicion that angiotensin II, either circulating or locally within blood vessels might contribute to the development of atherosclerotic lesions. Indeed angiotensin II has many actions which might promote atheroma formation. Furthermore, expression of angiotensin II in the intima is inhanced in atheromatous plaques, 253 chymase dependent angiotensin II formation is increased in human atherosclerotic aorta 254 and antagonism of AT 1 receptors reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. 255 Warnholtz et al 256 suggest that angiotensin II mediated superoxide production might play a pivotal role in the early stages of atherosclerosis.
These brief comments should serve to justify the confident prediction that this broad field will in the near future be further investigated, intensively and profitably, concerning both pathophysiological and therapeutic understanding.
Local renin-angiotensin systems
The preceding section on the endothelium will have at least partly served to emphasise the importance of local renin-angiotensin generation, and the interaction with other systems having physiological and pathological roles.
The previous understandable emphasis on the circulatory aspects of renin and angiotensin will henceforward be leavened by increased attention to local renin-angiotensin systems and their autocrine and paracrine functions.
Alternative pathways of angiotensin formation
There is longstanding, 83 and continuing, interest in routes alternative to those depicted in Figure 1 for the generation of active angiotensins. For example, in human resistance arteries angiotensin II can be formed via either ACE or chymase. It has however been shown that in patients with cardiac failure, the contractile response in resistance arteries to angiotensin I is blunted in the presence of the ACE inhibitor enalaprilat, suggesting that chymase cannot fully compensate for and hence override ACE inhibition. 257 These and like subjects will remain under close future scrutiny.
Overexpression of the AT 1 receptor
It was shown by Hein et al 258 that overexpression of the AT 1 receptor in mice was associated with an increase in atrial size, hyperplasia of myocytes within the atria and heart block. The implications of this observation for human disease are presently unclear.
Blockade of AT 1 receptors
Drugs blocking AT 1 receptors 104 are characterised by a particular lack of significant side effects which might translate into a comparatively superior compliance rate 259 -a vital factor in preventing the complications of hypertension. Whether, for compliant patients, the angiotensin II receptor blockers prove more or less effective in preventing complications remains to be determined. Likewise, whether these drugs are more or less effective than the ACE inhibitors after acute myocardial infarction should become clear from the results of ongoing studies. In established heart failure, ELITE I suggested that losartan might be associated with a lower mortality than captopril in elderly heart failure patients. 260 However, an appropriately powered study with mortality as its end point showed no such difference between losartan and captopril, although the former had the superior side effect profile. 261 In theory, the combination of an ACE inhibitor and an angiotensin II receptor blocker might prove superior to either drug alone in the above disorders, and formal trials indeed are underway.
The angiotensin II AT 2 receptor
The AT 1 receptor for angiotensin II mediates those responses shown in Figure 2 . The functions of the AT 2 receptor hitherto have by contrast remained comparatively obscure. The recent increasing use of orally-active AT 1 receptor blocking agents, which will expose AT 2 receptors to stimulation, has simultaneously provided a means to elucidate the functions of the latter and to evaluate resultant benefits or disadvantages. [105] [106] [107] [108] [109] [110] Such matters urgently require, and will receive, attention. Early results, which were mentioned briefly above, [105] [106] [107] [108] [109] [110] indicate that unopposed stimulation of AT 2 receptors by angiotensin II is a vasodilator, and hence probably additionally antihypertensive. Other likely actions mediated via the AT 2 receptor are shown in Table 1 . These aspects will undoubtedly soon be investigated in detail.
Renin inhibitors
We predicted in 1993 3 that effective orally-active inhibitors of the enzyme renin itself would be developed and introduced into clinical therapeutics. Though a range of renin inhibitors has appeared, 58, 59 none so far has been sufficiently well absorbed by mouth or long-acting for such application. Meanwhile angiotensin II AT 1 receptor blocking drugs have become well-established. 105 Nevertheless, there remains a need and an opportunity for improved renin inhibitors. The very diversity and complexity of the renin-angiotensin system calls for a range of different agents capable of interrupting that system at several sites. Continued development of renin inhibitors should thus still be pursued.
Standardisation
A long-standing and much repeated plea, [262] [263] [264] [265] almost as often ignored, is for the general adoption of a renin standard, enabling results to be expressed in common, quantitative, terms. It is truly shameful that we remain largely unable to compare the results of renin assays from time to time, or from one laboratory to another.
We here express the hope, but not regrettably the prediction, that such standardisation will be accepted, and implemented, before the second century of research into the renin-angiotensin system is ended.
Conclusions
This account has necessarily dealt only briefly with a number of intricate and potentially weighty issues, and some possibly important aspects have escaped mention. It is a personal review, and other writers would no doubt have selected and emphasised other topics.
We hope nevertheless that we have provided a not wholly inaccurate perspective of the progressive acquisition of knowledge and understanding of the renin-angiotensin system over the past century; of foci of current interest and investigation; and some, possibly rash, predictions of likely future revelations.
